Nuclera joins Tech Nation’s Future Fifty program

The FDA re­ject­ed lin­voseltam­ab, Re­gen­eron’s ex­per­i­men­tal an­ti­body for mul­ti­ple myelo­ma, the com­pa­ny an­nounced Wednes­day morn­ing. In an earn­ings call ear­li­er this … Sign up to

Neu­ro­crine’s lead neu­roen­docrinol­o­gy pro­gram has passed its first Phase III test, set­ting up a po­ten­tial FDA fil­ing in 2024. The San Diego biotech saw its